ERNA Projected Dividend Yield
Eterna Therapeutics Inc ( NASDAQ : ERNA )Eterna Therapeutics is a preclinical-stage biopharmaceutical company focusing on realizing the potential of mRNA cell engineering to provide patients with new medicines. Co. has in-licensed a portfolio of over 100 patents covering primary mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing proteins, and the ToRNAdo™ mRNA delivery system. Co. has a cell line customization and license agreement with Lineage Cell Therapeutics, Inc. (Lineage), pursuant to which, Lineage may request that Co. develops for, and deliver to, Lineage certain induced pluripotent stem cell lines. 21 YEAR PERFORMANCE RESULTS |
ERNA Dividend History Detail ERNA Dividend News ERNA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |